Cited by 182Computational Drug Discovery MethodsMachine Learning in Materials ScienceProtein Degradation and Inhibitors

Structure-based drug design with geometric deep learning

Open access
Isert, Clemens, Atz, Kenneth, Schneider, Gisbert·2023·Current Opinion in Structural Biology

Abstract

Structure-based drug design uses three-dimensional geometric information of macromolecules, such as proteins or nucleic acids, to identify suitable ligands. Geometric deep learning, an emerging concept of neural-network-based machine learning, has been applied to macromolecular structures. This review provides an overview of the recent applications of geometric deep learning in bioorganic and medicinal chemistry, highlighting its potential for structure-based drug discovery and design. Emphasis is placed on molecular property prediction, ligand binding site and pose prediction, and structure-based de novo molecular design. The current challenges and opportunities are highlighted, and a forecast of the future of geometric deep learning for drug discovery is presented.

Integrity signals

Registry

Crossref · 10.1016/j.sbi.2023.102548

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Isert, C., Atz, K., & Schneider, G.
Affiliations
ETH Zurich (CH)
Corresponding author
Schneider, Gisbert
Venue
Current Opinion in Structural Biology
Publisher
Elsevier BV
Published
2023-04
Volume
79
Pages
102548
ISSN
0959-440X (ISSN-L)
OpenAlex
W4321769975
Cited by
182
References
5
Citations by year
2026: 43 · 2025: 51 · 2024: 65 · 2023: 23
FWCI
3.06
Type
journal article
Language
en
Open access
Locations
  • Current Opinion in Structural Biology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (182176)
Topics
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
structure-based drug design, geometric deep learning, molecular property prediction, ligand binding site prediction, binding pose prediction, de novo molecular design, macromolecular structure, proteins, nucleic acids
MeSH terms
Machine Learning, Deep Learning, Ligands, Drug Design, Neural Networks, Computer, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review